Quote: Rock Creek Pharmaceuticals Announces European Patent Allowance for the Administration of Anatabine to Treat Autism Spectrum and Seizure Disorders and Third Quarter Results
SARASOTA, Fla., Nov. 9, 2015 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (OTCPK: RCPI), a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, announced today its third quarter results. The Company also disclosed the Notification of Intent to Grant by the European Patent Office of a European patent for the administration of Anatabine to treat autism spectrum and seizure disorders.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.